10.37k followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Johnson & Johnson
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Vir Biotechnology, Inc.
Inovio Pharmaceuticals, Inc.
Stock futures were little changed Tuesday evening, struggling for direction after equities sputtered into the close earlier in the day.
There are many pharmaceutical companies are pursuing a vaccine, and the market has already started rewarding some of them. For instance, Novavax (NASDAQ: NVAX) is up a startling 2,500% in 2020. Novavax is not the only winner, however.
Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”
South Korea has asked Gilead Sciences Inc's to supply enough of its anti-viral drug remdesivir to treat more than 5,000 COVID-19 patients in preparation for a potential second wave of infections, an opposition lawmaker said on Wednesday. One of the few treatments shown to alter the course of COVID-10, remdesivir is in high demand, but there are concerns about its availability after Gilead allocated nearly all of its supply to the United States over the next three months. In a letter sent to Gilead on June 3, South Korea had requested doses for 360 patients who are in urgent need of the drug, and for enough to have ready for an additional 5,000 patients in the event of a second wave of infections.
China's Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday. Last month, Clover became the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials by launching a study in Australia to test its vaccine with boosters. The foundation said the funding aims to help produce hundreds of millions of doses of the potential vaccine per year and if the early stage trials are successful, it expects to provide "significant" additional support.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and PrEP utilization on HIV prevention strategies and associated risk behaviors. Findings presented included results from an online survey conducted by The American Academy of HIV Medicine (AAHIVM) to understand potential changes in behavior among pre-exposure prophylaxis (PrEP) users and prescribers in the United States during the height of COVID-19 SIPOs. There were 598 total respondents – 409 PrEP users and 189 PrEP prescribers. While most prescribers (90 percent) reported recommending no change in PrEP regimen, about one-third (33 percent) of PrEP users discontinued therapy voluntarily, mostly (85 percent) due to low perceived HIV risk associated with decreased sexual activity. Only 8 percent of those users who discontinued PrEP cited inability to access PrEP medications. Nearly all prescribers (95 percent) were able to successfully prescribe PrEP despite limitations caused by SIPOs.
What happened Inovio Pharmaceuticals (NASDAQ: INO) stock skyrocketed 82.7% in June, according to data from S&P Global Market Intelligence. The S&P 500 returned 2% last month. In July, shares of the coronavirus vaccine developer, however, have given back a chunk of last month's gain: Through Tuesday, July 7, they're down nearly 11%, while the broader market has returned just over 3%.
The two sides are apparently arguing over several issues, including protocols and information sharing.
GlaxoSmithKline (NYSE: GSK) announced Tuesday that Medicago -- a private company owned by Mitsubishi Tanabe Pharma (OTC: MTZXF) and Philip Morris International (NYSE: PM) -- will use GlaxoSmithKline's adjuvant in a COVID-19 vaccine it expects to enter phase 1 trials this month. Medicago's recombinant coronavirus "Virus-Like Particles" will be combined with Glaxo's pandemic adjuvant system to boost immune response, potentially allowing for less antigen per dose and thus, more available vaccine doses.
In the latest trading session, Johnson & Johnson (JNJ) closed at $142.85, marking a -0.09% move from the previous day.
Pfizer (PFE) closed the most recent trading day at $34.03, moving -1.39% from the previous trading session.
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
U.S. stocks fell on Tuesday, adding to losses into the close, as investors took profits a day after the S&P 500 logged its longest streak of gains this year and as new U.S. coronavirus cases rose further. Large parts of the United States reported tens of thousands of new coronavirus infections. Mester said during an interview with CNBC that a resurgence in coronavirus cases across the country is making consumers more cautious, and more fiscal stimulus is needed to help the economy recover fully from the crisis.
U.S. stocks eased on Tuesday as investors took profits a day after the S&P 500 logged its longest streak of gains this year and as new U.S. coronavirus cases rose further. Large parts of the United States reported tens of thousands of new coronavirus infections.
U.S. stocks eased on Tuesday as investors took profits a day after the S&P 500 logged its longest streak of gains this year and as new U.S. coronavirus cases rose further. Large parts of the United States reported tens of thousands of new coronavirus infections. The Nasdaq was outperforming the other two main indexes, hovering between gains and losses but claiming another record high.
The S&P 500 eased on Tuesday, a day after the benchmark index logged its longest streak of gains this year as investors weighed the risk of a sharp jump in new coronavirus cases nationwide hindering a rebound in economic activity. The Nasdaq, on the other hand, claimed another record high, boosted by shares of technology heavyweights Microsoft Corp and Apple Inc. The Dow Industrials dropped 0.8%, weighed down by cyclical stocks including Goldman Sachs and Boeing Co. Large parts of the country reported tens of thousands of new coronavirus infections.
Efforts to find treatments for the COVID-19 pandemic have taken top priority at many companies in the space, and today, Novavax (NASDAQ: NVAX) and Regeneron Pharmaceuticals (NASDAQ: REGN) got good news from the federal government. Novavax shares were up more than 30% Tuesday morning as investors reacted positively to the latest news from the biotech. As a major player in the race to find a coronavirus vaccine, Novavax got a shot in the arm from the Department of Health and Human Services.
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
The S&P 500 was little changed on Tuesday a day after the benchmark index logged its longest streak of gains this year, as investors weighed expectations of an economic recovery against risks from a sharp jump in new coronavirus cases nationwide. The tech-heavy Nasdaq, on the other hand, claimed another record level, boosted by shares of Microsoft Corp and Apple Inc while the Dow Industrials dropped 0.7% weighed down by Goldman Sachs and Boeing Co. Bank stocks, whose performance is linked to the outlook for the economy, dropped 2.5%.
Energy stocks dropped 2% on worries over fuel demand while travel-related stocks, which were among the hardest hit during lockdowns, also fell. U.S. stocks have climbed despite an alarming rise in coronavirus cases as a surprise expansion in the U.S. service sector and a record job additions in June are among the slate of upbeat data recently that have bolstered views that an economic recovery is underway. The Nasdaq reclaimed its record high last month.
India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday. At current capacity, Sovereign can supply 50,000 to 95,000 vials per month of the injectable, the company said in an emailed statement on Tuesday. It did not disclose how many vials are there in the batch for Cipla.
(Bloomberg) -- Novavax Inc., one of the front-runners in the race to develop a Covid-19 vaccine, will receive $1.6 billion from the U.S. government, the biggest contribution yet from the Operation Warp Speed program.The funds will allow the company to conduct advanced human studies and establish manufacturing to deliver 100 million doses as soon as late 2020, Gaithersburg, Maryland-based Novavax said in a statement.Shares of Novavax rose as much as 41%, the highest since September 2016, in Tuesday trading.Novavax is among companies striving to develop an inoculation against the novel coronavirus that’s spreading quickly in countries including the U.S., India and Mexico. President Donald Trump’s Warp Speed program has backed efforts at a number of companies, including Johnson & Johnson, Merck & Co., Pfizer Inc., Moderna Inc. and AstraZeneca Plc, to get doses as early as possible.Operation Warp Speed seeks to compress a process that is typically years long into a matter of months. The drive is being led by General Gustave Perna, who directs the U.S. Army Materiel Command, and former GlaxoSmithKline Plc executive Moncef Slaoui.Spike ProteinThe funds will help Novavax begin a final-stage study of its vaccine candidate as early as this fall, with as many as 30,000 subjects, according to the statement.The biotech company earlier secured as much as $388 million in May from the Coalition for Epidemic Preparedness Innovations, the single largest contribution from the organization at the time. The company’s vaccine candidate is meant to provoke the production of antibodies that block the “spike” protein the coronavirus uses to infect host cells.Separately, Regeneron Pharmaceuticals Inc. secured a $450 million award from the program under the auspices of the U.S. Biomedical Advanced Research and Development Authority, or BARDA. The Tarrytown, N.Y.-based company will use the funds to scale up production of an antibody cocktail to prevent infection.Analysts are expecting results from Regeneron’s antibody program sometime in the third quarter. Novavax, which has yet to commercialize a medicine or vaccine, plans to report a first look at its results in patients later this month.Drug companies and university researchers are investigating more than 140 experimental inoculations, according to the World Health Organization. Moderna, Pfizer and the University of Oxford, working with AstraZeneca, are among the companies and institutions that have started studies of their vaccines in healthy patients.(Updates shares in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The stock market fell Tuesday, but is a sustained pullback in the offing. Tesla and EV rival Nio keeps moving early. Facebook is in focus after execs met with ad boycott organizers.